Basic Donepezil Information

• INN (International Nonproprietary Name): Donepezil
• Brand Names Available In United Kingdom: Aricept; Aricept Evess (orodispersible tablet); Donepezil Teva; Donepezil Mylan; Donepezil Sandoz; generics from multiple suppliers; note that Adlarity is a transdermal patch marketed in the US and is of growing interest in the UK market.
• ATC Code: N06DA02
• Forms & Dosages: Film-coated tablets 5mg and 10mg; Orodispersible tablets 5mg and 10mg; Extended-release transdermal patch 5mg/24hr and 10mg/24hr; Combination capsule with memantine (Namzaric-style) containing donepezil 10mg plus memantine in regions where marketed.
• Manufacturers In United Kingdom: Multiple suppliers and generics are available from companies including Pfizer, Eisai Co., Ltd., Teva, Sandoz, Mylan, Accord, Macleods Pharma and Sun Pharma; Aricept Evess is present in the UK market for ODT use.
• Registration Status In United Kingdom: Donepezil is registered and available under MHRA oversight; EMA/UK product listings and local formularies list both originator and generics for prescription use.
• OTC / Rx Classification: Prescription-Only Medicine (Rx) in the United Kingdom and most jurisdictions listed.

Key Findings From Recent Trials

Major 2022–2025 Studies

What have recent clinical trials actually shown about donepezil?

High‑quality randomised controlled trials from 2022–2025 emphasise two practical trends: formulation innovation — especially transdermal delivery — and modest but consistent symptomatic benefit in mild to moderate Alzheimer’s disease.

Patch studies led to regulatory activity internationally, and combination trials pairing donepezil with memantine reported additive benefits in selected moderate–severe cohorts.

These trials typically compared donepezil tablets or ODTs with newer delivery systems such as patches and evaluated cognitive scales and caregiver‑reported outcomes.

Main Outcomes

How much improvement can clinicians and carers expect?

Meta‑analyses in this period reaffirm small‑to‑moderate symptomatic improvements on cognitive instruments such as ADAS‑Cog and on global impression scales.

Clinical gains most often appear within the first 6–12 months and then tend to plateau.

Functional and caregiver burden metrics show variable change, with clinically meaningful benefits in selected subgroups rather than universal functional recovery.

Safety Observations

Are there new safety issues with modern donepezil use?

Gastrointestinal effects — nausea and diarrhoea — remain the most reported adverse events with oral dosing.

Cardiovascular issues such as bradycardia and syncope continue to be important monitoring points.

Transdermal patch trials show fewer GI complaints but a higher incidence of local skin reactions at the application site.

Regulatory guidance is increasingly recommending personalised formulation choice to balance tolerability and adherence.

Clinical Mechanism Of Action

Layman’s Explanation

What does donepezil do in plain language?

Donepezil is an acetylcholinesterase inhibitor that raises levels of acetylcholine in the brain, which can improve memory, attention and thinking for a time in people with Alzheimer’s disease.

It helps surviving brain cells communicate better but does not reverse the underlying neurodegeneration causing the disease.

Scientific Breakdown

How does donepezil work at a biochemical level?

Donepezil (ATC N06DA02) reversibly inhibits acetylcholinesterase, increasing synaptic acetylcholine in cortical and hippocampal circuits involved in cognition.

Oral tablets and orodispersible formulations have high bioavailability and are metabolised hepatically.

Transdermal systems deliver steady plasma levels over 24 hours and reduce peak‑related adverse events compared with oral dosing.

At therapeutic doses central AChE inhibition is incomplete, which explains residual peripheral cholinergic effects such as nausea and bradycardia.

Combination with memantine targets both cholinergic and NMDA glutamatergic pathways, which is the rationale for Namzaric‑style therapy in moderate–severe disease.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

Who is prescribed donepezil in the UK and how is it available?

Donepezil is a prescription‑only medicine widely used for symptomatic treatment of mild to moderate Alzheimer’s disease in the UK.

Active products in the UK market include Aricept tablets and Aricept Evess orodispersible tablets, alongside multiple generics such as Donepezil Teva, Donepezil Mylan and Donepezil Sandoz.

Transdermal systems such as Adlarity are approved in the US and are of growing clinical interest in the UK, though NHS adoption varies by commissioning and NICE guidance.

Combination products with memantine are used selectively for moderate to severe disease where memantine is clinically indicated.

Notable Off‑Label Trends

Do prescribers use donepezil for anything else?

Off‑label use is uncommon and typically limited to difficult‑to‑treat swallowing issues where orodispersible tablets or individual funding requests for patch access may be considered.

Use in non‑Alzheimer’s cognitive impairment, such as certain vascular cognitive syndromes, is not supported by robust evidence and is rarely standard practice.

Formulary and commissioning decisions in the UK prioritise licensed indications, cost‑effectiveness and appropriate monitoring for safety.

Dosage Strategy

General Dosing

What is the usual start and escalation schedule?

Initiate at 5mg once daily, commonly taken at bedtime, and reassess after 4–6 weeks for escalation to 10mg once daily if tolerated.

The standard oral maximum dose in common use is 10mg daily, though some regions may use a 23mg extended‑release formulation less commonly in the UK.

Choose orodispersible tablets for swallowing difficulties, and consider transdermal patches when oral tolerance or adherence is problematic.

Condition‑Specific Dosing

How does dosing change with severity and comorbidity?

Mild–moderate Alzheimer’s disease: start 5mg, increase to 10mg for greater symptomatic effect when tolerated.

Moderate–severe disease: continue 10mg and consider combination with memantine where indicated for broader symptom management.

Special populations: elderly patients generally require no initial dose reduction but need monitoring for cardiac and hepatic comorbidity; renal impairment usually requires no adjustment; severe hepatic impairment calls for caution and closer observation.

Safety Protocols

Contraindications

Who should not be given donepezil?

Absolute contraindications are known hypersensitivity to donepezil hydrochloride or to piperidine derivatives and severe allergic reactions to excipients.

Use with caution in patients with cardiac conduction disorders such as sick sinus syndrome or a history of AV block.

Also exercise caution in severe asthma or COPD, active peptic ulcer disease, urinary outflow obstruction and patients with seizure histories.

Adverse Effects

What adverse effects should carers and prescribers watch for?

Common adverse effects include gastrointestinal symptoms — nausea, vomiting, diarrhoea and anorexia — along with insomnia, dizziness, vivid dreams and fatigue.

Muscle cramps and headaches occur in some patients.

Clinically significant events include symptomatic bradyarrhythmias and syncope, which require baseline pulse checks and ECG if there is a cardiac history.

Patch users may experience local skin reactions more often than oral users.

Management includes monitoring pulse and weight, reviewing concurrent medicines that lower heart rate, and educating carers to report severe reactions promptly.

Interaction Mapping

Food Interactions

Are there foods to avoid?

Donepezil has no major food restrictions and may be taken with or without food.

Orodispersible tablets behave like standard tablets in relation to absorption.

Transdermal patches bypass the gastrointestinal tract, which is useful when food intake is unpredictable or when oral administration is difficult.

Drug Combinations To Avoid

Which drug combinations require caution?

Concomitant cholinergic drugs can potentiate effects, and beta‑blockers, digoxin and other negative chronotropes increase the risk of bradycardia.

Anticholinergic medications (for example some antihistamines, tricyclic antidepressants, and oxybutynin) antagonise donepezil’s central benefit and may reduce clinical efficacy.

Strong CYP2D6 or CYP3A4 inhibitors or inducers can alter donepezil metabolism; monitor clinically although routine dose changes are uncommon.

Inform anaesthetists that the patient takes donepezil, because perioperative cardiac monitoring may be advised in some cases.

Combination therapy with memantine is established and requires coordinated clinical oversight rather than avoidance.

Patient Experience Analysis

Survey Data

Do patients and carers feel it helps?

UK‑based patient and carer surveys report modest perceived cognitive stabilisation during the first 6–12 months of therapy in many cases.

Improved day‑to‑day functioning and communication are reported by a subset of carers, and adherence closely correlates with tolerability.

Gastrointestinal side effects are a common reason for early discontinuation according to surveys and service audits.

Forum Trends

What do online communities say about formulation and side effects?

Forum reports commonly stress three themes: formulation matters, side‑effect vigilance, and mixed expectations about treatment goals.

Patients and carers often prefer ODTs or patches when swallowing is an issue or when oral GI intolerance develops.

Patch users frequently note fewer GI complaints but more skin irritation.

Clinicians should set realistic expectations, explain that donepezil is symptomatic rather than curative, and tailor formulation to individual needs.

Distribution And Pricing Landscape

UK Distribution

How is donepezil supplied to UK patients and services?

Donepezil is prescription‑only and available via NHS prescriptions and private pharmacies across the UK.

Generics from manufacturers such as Teva, Mylan and Sandoz are widely supplied, and typical pharmacy pack sizes include 28‑tablet blisters for community patients and 100‑tablet bottles for institutional use.

Aricept Evess orodispersible tablets are stocked to help patients with dysphagia.

Pricing And Market Dynamics

What affects cost and availability?

Generics have reduced the cost of standard tablets, improving affordability on the NHS and privately.

Newer formulations such as transdermal patches (Adlarity) and combination products like Namzaric command premium pricing and may require local commissioning decisions or individual funding on the NHS.

Pharmacies should check the NHS Drug Tariff and local formulary guidance for current reimbursement and supply status.

In our online pharmacy, donepezil is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

Which alternatives should prescribers consider?

Rivastigmine is another cholinesterase inhibitor available both orally and as a transdermal patch and may be preferred when patch delivery is desired.

Galantamine is an acetylcholinesterase inhibitor with additional nicotinic modulation and requires careful titration.

Memantine is an NMDA antagonist indicated for moderate–severe Alzheimer’s disease and is often used in combination with donepezil for broader symptom control.

Tacrine is largely obsolete because of hepatotoxicity risk and is not used in modern practice.

Pros And Cons

How does donepezil compare at a glance?

Pros: Well‑studied efficacy, multiple formulations including tablets, ODTs and interest in patches, widespread generic availability.

Cons: Limited effect size, peripheral cholinergic side effects, and cardiac caution in susceptible patients.

Choice of agent should be driven by formulation tolerance, comorbidity profile and ease of adherence.

Regulatory Status

Global And UK Regulatory Snapshot

Who has approved donepezil and where?

Donepezil is licensed globally for Alzheimer’s disease and appears on registries of the US FDA, EMA, PMDA (Japan), Health Canada, TGA (Australia) and the MHRA in the UK.

ATC classification is N06DA02 and brand examples include Aricept, Aricept Evess, and generics from several manufacturers.

Adlarity transdermal patches are approved in the US, with UK adoption depending on NICE appraisal and local commissioning.

Prescription Status And Pharmacovigilance

What legal and safety reporting applies?

Donepezil is a prescription‑only medicine in the UK.

Adverse events should be reported to the MHRA Yellow Card scheme, and marketing authorisation holders provide periodic safety updates according to pharmacovigilance requirements.

Consolidated FAQ

Common Prescriber Questions

How quickly do patients respond?

Measurable cognitive and functional effects typically emerge within weeks to months, with most trial signals evident within 6–12 months.

Is abrupt stopping a problem?

A gradual taper is not required medically, but clinicians should monitor for loss of benefit and discuss cessation with carers.

Carer And Patient Questions

Which formulation is best for swallowing problems?

Orodispersible tablets such as Aricept Evess or transdermal patches are suitable choices for patients with dysphagia.

Will donepezil cure Alzheimer’s?

No; donepezil provides symptomatic benefit but does not modify the underlying disease process.

Who should not take donepezil?

Patients with known hypersensitivity to donepezil or severe cardiac conduction abnormalities should not receive it; check product information for full contraindications.

Visual Guide

Recommended Visuals

Which images make this easier to understand?

Include a comparative diagram of formulations showing film‑coated tablet, orodispersible tablet and transdermal patch with dosing examples (5mg/10mg; patch 5mg/24hr and 10mg/24hr).

Add a simple mechanism infographic showing acetylcholinesterase inhibition in the hippocampus and cortex.

Create an adverse‑event risk matrix highlighting GI, cardiac and CNS risks and a flowchart for formulation selection based on swallowing, GI tolerance and adherence.

Key Labels And Packaging To Show

Which product images are useful?

Where licensing permits, use images of Aricept blister packs, Aricept Evess ODT blister strips and unit‑dose patches such as Adlarity for patient education.

Patient leaflets should show how to apply patches, rotate sites and how to use orodispersible tablets from the blister.

Storage And Transport

Recommended Conditions

How should donepezil be stored?

Store at room temperature, 15–30°C, in a dry place away from direct light and keep out of reach of children.

These conditions apply to tablets, orodispersible tablets and transdermal patches.

Handling Practicalities

Any tips for patients, carers or pharmacies?

Keep ODTs in their blister until use and instruct carers that patches should be applied to clean, dry skin and rotated to different sites to reduce local irritation.

Preserve original packaging with batch and expiry information for pharmacovigilance and avoid exposing patches and tablets to extremes of temperature or humidity during transport.

Dispose of unused medicines through community pharmacy returns; do not flush patches or tablets.

Guidelines For Proper Use

Prescribing Checklist

What should prescribers tick off before starting treatment?

• Confirm diagnosis of Alzheimer’s disease and that donepezil is indicated.
• Check cardiac history and perform ECG if conduction disease is suspected.
• Review concomitant medicines for interactions (beta‑blockers, anticholinergics).
• Select formulation (tablet, ODT, patch) based on swallowing, tolerance and adherence.
• Start 5mg nightly and schedule a 4–6 week review for potential up‑titration to 10mg.

Monitoring And Follow‑Up

How should patients be followed up once started?

Review at 4–6 weeks after initiation and again at 3–6 months to assess cognition, function, weight and adverse effects.

Reassess benefit annually and consider deprescribing if there is clear lack of benefit or intolerable side effects.

Report serious or unexpected adverse events to the Yellow Card scheme and consult local NHS formulary guidance for commissioning queries such as patch access.

Delivery Across United Kingdom

City	Region	Delivery Time
London	Greater London	5-7 days
Birmingham	West Midlands	5-7 days
Manchester	Greater Manchester	5-7 days
Glasgow	Scotland	5-7 days
Leeds	West Yorkshire	5-7 days
Sheffield	South Yorkshire	5-7 days
Liverpool	Merseyside	5-7 days
Bristol	South West England	5-7 days
Newcastle Upon Tyne	North East England	5-7 days
Cardiff	Wales	5-7 days
Belfast	Northern Ireland	5-7 days
Norwich	East of England	5-9 days
Plymouth	South West England	5-9 days